Clinical trials
Acute Myeloid Leukemia clinical trials
Below are recruiting acute myeloid leukemia clinical trials, each written for real people, not researchers. We’re tracking 598 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07198867RecruitingPhase 1
A-CAR028 for relapsed or refractory AML
This trial tests a new cell therapy called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses your own immune cells to fight the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT07183878Recruiting
Venetoclax with BUCY conditioning for high-risk AML or MDS transplant
This trial tests whether adding venetoclax (a pill that targets cancer cells) to the standard chemotherapy regimen before a stem cell transplant improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It is for patients aged 12–60 whose cancer has specific high-risk features and who have a matched donor.
Hangzhou, ZhejiangAges 12–60 - NCT07177079RecruitingPhase 1
High-dose vitamin C with standard therapy for newly diagnosed AML
This trial tests adding high-dose vitamin C (ascorbate) to the standard two-drug treatment (azacitidine and venetoclax) for people with newly diagnosed acute myeloid leukemia who are not candidates for intensive chemo. The goal is to see if the vitamin C makes the standard treatment work better and helps control the leukemia.
Iowa City, IowaAges 18–75 - NCT05907057RecruitingPhase 3
Ivosidenib plus azacitidine for newly diagnosed AML
This trial studies ivosidenib together with azacitidine in people newly diagnosed with AML that has an IDH1 R132 gene mutation. It’s meant for patients who are not able to safely receive the strongest (intensive) chemotherapy, with the goal of improving control of the leukemia.
ViennaAges 18 years+ - NCT07148180RecruitingPhase 1/Phase 2
Targeting leftover leukemia cells with a combination therapy
This trial tests a new drug combo (tagraxofusp, azacitidine, and venetoclax) for people with acute myeloid leukemia (AML) who have very small amounts of cancer cells still present after initial treatment. The goal is to see if it can clear these leftover cells and prevent the cancer from coming back.
Boston, MassachusettsAges 18 years+ - NCT07137637RecruitingPhase 1
HPB-092 for relapsed or refractory AML
This trial tests a new drug, HPB-092, in adults with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see if it can help when other treatments have not worked.
TianjinAges 18 years+ - NCT07144020RecruitingEarly Phase 1
Donor CAR-T cells for relapsed or refractory AML
This trial tests a new treatment using your donor's immune cells that are engineered to find and attack cancer cells with a specific marker called CD117. It's for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT07107126RecruitingPhase 1
Testing a new drug for relapsed AML or high-risk MDS
This trial tests a new drug called RPT1G for adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that have not responded to standard treatments. The goal is to see if the drug is safe and if it shows signs of helping control the disease.
New York, New YorkAges 18 years+ - NCT07108530RecruitingPhase 2
Chemotherapy and transplant for adult acute myeloid leukemia
This trial tests a combination of chemotherapy and stem cell transplant for adults with acute myeloid leukemia (AML) that is not a specific subtype called APL. It aims to see if this approach is more effective than standard treatments.
Taiyuan, ShanxiAges 14–65 - NCT07106749RecruitingPhase 1
CD180 car T cells for blood cancers that came back
This trial tests a new CAR T cell therapy that targets a protein called CD180 on cancer cells. It is for people with certain types of relapsed or refractory leukemia or lymphoma that has not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT05794880Recruiting
Immunotherapy lowering immune cells before transplant in children
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
Milwaukee, WisconsinAges birth–25 years - NCT07584889RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Relapsed Blood Cancers
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
Shenzhen, Other (Non U.s.)Ages 18–75 - NCT06222580RecruitingPhase 1
Combination of two targeted drugs for resistant FLT3-mutated AML
This trial tests a combination of two targeted drugs, SNDX-5613 and gilteritinib, for people whose AML has come back or hasn't responded to treatment. It is for those with an FLT3 gene mutation plus another specific genetic change like NPM1 or MLL. The study aims to see if this two-drug approach works better when used together.
Chapel Hill, North CarolinaAges 18 years+ - NCT07094750Recruiting
Comparing treatment intensities for less fit adults with AML
This study compares different treatment intensities for adults with acute myeloid leukemia (AML) who are less able to handle strong chemotherapy. It aims to find the best approach for people with health issues like heart or lung problems that make standard chemo riskier.
Seattle, WashingtonAges 18 years+ - NCT07080970Recruiting
Observational study of AML with NPM1 mutation
This study is observing leukemia patients who have a certain gene change (NPM1 mutation) to better understand their disease and early blood vessel problems.
FlorenceAges 18 years+ - NCT06928662RecruitingPhase 1/Phase 2
Chemo, radiation, and donor stem cell transplant for high-risk blood cancers
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
Seattle, WashingtonAges 18 years+ - NCT07060001RecruitingPhase 2
Comparing two leukemia treatments using a blood test
This trial compares two standard treatments for newly diagnosed acute myeloid leukemia (AML) to see if a simple blood test can help predict how well each treatment works. The goal is to find the best treatment approach for each person.
Houston, TexasAges 18 years+ - NCT03326921RecruitingPhase 1
T cell treatment for leukemia after a bone marrow transplant
This early-phase trial tests an immune “T cell” therapy made to recognize a specific leukemia target. It is for people whose acute leukemia has come back (relapsed) or did not fully respond after receiving a donor stem cell transplant.
Seattle, WashingtonAges Up to 80 years - NCT07044687RecruitingPhase 4
Venetoclax with azacitidine for newly diagnosed AML
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
Gurgaon, HaryanaAges 18 years+ - NCT07046078RecruitingPhase 2
Chemo, radiation, and donor transplant for older adults with high-risk AML
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
Seattle, WashingtonAges 18 years+ - NCT07044544RecruitingPhase 1
New drug combo in stem cell transplant for myeloid cancers
This trial tests adding two new drugs, decitabine and venetoclax, to a standard reduced-intensity stem cell transplant for people with certain types of leukemia or myelodysplastic syndrome. The goal is to see if this combination can improve outcomes.
Birmingham, AlabamaAges 18–75 - NCT07036250RecruitingPhase 1/Phase 2
Study of U32 for acute myeloid leukemia
This trial tests a new treatment called U32 for people with acute myeloid leukemia (AML) that has come back or not responded to prior therapy. It aims to see if targeting certain proteins on leukemia cells can help control the disease.
SuzhouAges 2–65 - NCT07025564RecruitingPhase 1
MiRisten for relapsed or refractory AML
This phase 1 trial tests a new treatment called MiRisten for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07028086RecruitingPhase 2
VAM for secondary or extramedullary AML
This trial tests a combination of three drugs (called VAM) in people whose acute myeloid leukemia (AML) is either secondary (came from another blood disorder), therapy-related (caused by previous cancer treatment), or has spread outside the bone marrow (extramedullary disease). It is for patients who have not yet received any treatment for their AML.
ShanghaiAges 18–65
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute myeloid leukemia?
- Yes. Clin2 currently lists 598 recruiting acute myeloid leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute myeloid leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute myeloid leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.